The graft versus host disease (GvHD) treatment market is evolving rapidly due to increasing stem cell and bone marrow transplants, the rising incidence of hematological malignancies, and advances in immunotherapy. GvHD, a common complication following allogeneic hematopoietic stem cell transplantation, can lead to severe morbidity and mortality. As medical research focuses on better outcomes...